Endpoints News ٢٦ فبراير ٢٠٢٦ Lilly's GLP-1 pill beats Novo’s in diabetes trial, has more side effects
Endpoints News ٢٤ فبراير ٢٠٢٦ Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to market
BioPharma Dive ٢٣ فبراير ٢٠٢٦ Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study
Endpoints News ٢٣ فبراير ٢٠٢٦ Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial
PharmaVoice ١٢ فبراير ٢٠٢٦ Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift
BioPharma Dive ٩ فبراير ٢٠٢٦ Lilly buys ‘in vivo’ CAR-T maker Orna, extending streak of genetic medicine deals
FierceBiotech ٩ فبراير ٢٠٢٦ Lilly, Innovent pen $8.8B oncology, immunology collab that 'moves beyond traditional licensing'